Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.
Alexander Ngwube, Niketa Shah, Kamar Godder...
https://pubmed.ncbi.nlm.nih.gov/32813873/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2026-05-29
29
Participants Needed
4
Research Sites
260 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of reduced intensity conditioning and familial HLA-mismatched bone marrow transplants in children and young adults under 21 years old with non-malignant disorders. These disorders include bone marrow failure syndromes, metabolic and immunologic disorders, hemoglobinopathies, and severe sickle cell disease. The study focuses on assessing donor cell engraftment and treatment toxicity in this population. Participants will receive a specific reduced intensity conditioning regimen that includes hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan over several weeks before undergoing a familial HLA-mismatched bone marrow transplant. After the transplant, they will receive a graft-versus-host disease GVHD prevention regimen with drugs such as cyclophosphamide, tacrolimus, mycophenolate mofetil, abatacept, and rituximab. Treatment and monitoring are planned for up to two years post-transplant. During the study, participants will be closely followed with regular assessments of donor engraftment at 100 days and one year after transplant. Researchers will also monitor neutrophil and platelet engraftment, pulmonary, hepatic, neurologic, cardiac, and renal function at multiple intervals. Pharmacokinetics of key drugs, incidence of acute and chronic GVHD, and immune system recovery will be evaluated. The total duration of participation and safety monitoring extends up to two years after the transplant.
CONDITIONS
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
S
Shalini Shenoy, MD
I
Ian Snyder, BS, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational regimen | Current practice comparator |
|---|---|---|
| What it is | Single‑group investigational regimen combining reduced‑intensity conditioning (hydroxyurea, alemtuzumab, fludarabine, thiotepa, melphalan) with familial HLA‑mismatched bone marrow transplant and multi‑agent GVHD prophylaxis including cyclophosphamide, tacrolimus, MMF, abatacept, and rituximab | Reduced‑intensity conditioning regimens (e.g. fludarabine‑based) followed by transplant with standard GVHD prophylaxis and sometimes post‑transplant cyclophosphamide |
| Role in trial | Investigational regimen being evaluated for safety, engraftment, and GVHD outcomes | Represents standard clinical practice used as context rather than trial‑assigned comparator |
| Primary use | To establish safety and donor engraftment at 100 days and 1 year post‑transplant in children with non‑malignant disorders lacking matched sibling donors | Used clinically to promote engraftment while minimizing toxicity and reducing GVHD risk in pediatric non‑malignant transplant |
| How it is given or performed | Conditioning agents given in sequence days –60 to 0, followed by bone marrow transplant, then multi‑agent GVHD prophylaxis through approximately day +390 per age‑based schedule | Fludarabine‑based conditioning followed by transplant and standard GVHD prophylaxis such as calcineurin inhibitor plus methotrexate or post‑transplant cyclophosphamide |
| Evidence status | Evidence limited to this early‑phase trial under investigation | Evidence supports abatacept added to standard prophylaxis reduces acute GVHD in similar pediatric non‑malignant transplant settings |
| Important risks | Risk of graft‑versus‑host disease, graft failure, regimen‑related toxicity including organ dysfunction | Risk of GVHD and transplant‑related toxicities remain despite standard prophylaxis |
| Important limitations | Single‑group early‑phase design without randomized comparator limits ability to compare effectiveness or safety directly | Existing evidence mainly observational or non‑randomized; generalizability and regimen variant differences may affect comparison |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 8 weeks before transplant (Days -60 to 0)
Participants receive a reduced intensity conditioning regimen with drugs including hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan prior to transplant.
Multiple visits during the conditioning period
Duration - From Day 0 through approximately 1 year post-transplant
Participants undergo a familial HLA-mismatched bone marrow transplant followed by graft-versus-host disease prophylaxis with cyclophosphamide, tacrolimus, mycophenolate mofetil, abatacept, and rituximab.
Multiple visits including 1 baseline visit at transplant and regular visits up to 1 year
Duration - Up to 2 years post-transplant
Participants are monitored for safety, donor cell engraftment, immune reconstitution, and organ function up to 2 years post-transplant.
Periodic visits at days +30, +60, +90, 1 year, 1.5 years, and 2 years post-transplant
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alexander Ngwube, Niketa Shah, Kamar Godder...
https://pubmed.ncbi.nlm.nih.gov/32813873/Washington University School of Medicine
Lead Sponsor